Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Bristol-myers squibb company symbols : Nktr save search
Natural Killer (NK) Cell Therapeutics Market to Perceive Healthy CAGR of 40.9% by 2029, Size, Share, Trends, Demand, Opportunities, Challenges and Competitive Analysis
Published: 2022-11-28 (Crawled : 07:00) - prnewswire.com
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: -0.62%
H: 1.04%
C: 0.41%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.05%
H: 0.53%
C: -0.18%
NKTX | $7.56 2.3% 2.12% 640K
|
Health Technology
|
| O: -0.46%
H: 2.09%
C: -6.26%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: -0.62%
H: 1.09%
C: -3.73%
therapeutics market
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
Published: 2022-04-29 (Crawled : 12:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -3.61%
H: 3.02%
C: 2.02%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: 2.43%
H: 2.84%
C: -2.13%
Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)
Published: 2022-04-14 (Crawled : 21:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.22%
H: 1.4%
C: 0.61%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: -0.81%
H: 2.21%
C: 0.65%
opdivo program nivolumab
Bristol Myers Squibb and Nektar Announce Update on Phase 3 PIVOT IO-001 Trial Evaluating Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab) in Previously Untreated Unresectable or Metastatic Melanoma
Published: 2022-03-14 (Crawled : 12:30) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: -54.79%
H: 0.0%
C: 0.0%
io-001 opdivo trial phase 3 nivolumab
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
Published: 2021-12-15 (Crawled : 15:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.18%
H: 2.11%
C: 1.66%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: 0.16%
H: 2.52%
C: 2.05%
EXEL | $23.29 1.84% 1.82% 1.9M
|
Health Technology
|
| O: -0.59%
H: 5.8%
C: 5.68%
xl092 solid tumors phase 1b trial phase 1 phase 2b
Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Published: 2021-08-05 (Crawled : 22:00) - biospace.com/
TEVA | $13.01 1.01% -0.62% 8.1M
|
Health Technology
|
| O: 0.5%
H: 2.84%
C: -0.7%
TAK | News | $13.38 0.15% 1.94% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.61%
C: 0.55%
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: 0.26%
H: 0.13%
C: -0.36%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: 0.77%
H: 1.33%
C: 0.83%
EXEL | $23.29 1.84% 1.82% 1.9M
|
Health Technology
|
| O: 0.0%
H: 2.03%
C: 1.25%
financial results results
Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Bristol Myers Squibb to Evaluate XL092 in Combination with Immuno-oncology Therapies in Advanced Solid Tumors
Published: 2021-06-14 (Crawled : 17:00) - biospace.com/
BMY | $48.99 -0.31% 0.41% 7.1M
|
Health Technology
|
| O: -0.03%
H: 0.19%
C: -0.04%
NKTR | News | $1.42 4.41% 3.89% 1.1M
|
Health Technology
|
| O: 0.62%
H: 2.31%
C: -0.23%
EXEL | $23.29 1.84% 1.82% 1.9M
|
Health Technology
|
| O: 0.48%
H: 1.08%
C: -1.43%
solid tumors collaboration trial therapy
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 26M
|
AGBA | $2.97 137.6% 57.48% 66M
|
Finance
EDBL | News | $6.59 75.27% 41.8% 2M
|
ZAPP | $4.44 50.2% 33.12% 370K
|
n/a
MTC | $2.24 43.59% 30.67% 6M
|
Technology Services
OPRT | News | $3.15 40.0% 29.13% 12M
|
Finance
SHIM | $3.045 35.33% 26.23% 870K
|
HKIT | $1.33 30.39% 24.16% 390K
|
Technology Services
ABVC | $1.35 29.81% 23.53% 7.1M
|
Wholesale Trade
OST | $0.5 25.0% 21.88% 280K
|
Your saved searches
Save your searches and get alerts when important news are released.